China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its chromosome aneuploidy detection kit (combined probe anchoring polymerization sequencing method). This marks a significant milestone in the company’s efforts to advance genetic testing solutions.
Product Profile
Chromosome abnormalities are closely related to birth defects, including adverse pregnancy outcomes such as spontaneous abortion, fetal structural abnormalities, and mental retardation. BGI Genomics’ detection kit is the first CNV seq detection kit based on high-throughput sequencing technology in China. It can be used for in vitro qualitative detection of trisomy 13, 16, 18, 21, 22, and monosomy X in human miscarriage villus tissue samples. The kit also supports library construction in the detection process, helping to prevent and control birth defects.
Future Development
The NMPA approval underscores BGI Genomics’ commitment to advancing innovative genetic testing solutions. By introducing this high-throughput sequencing detection kit, the company aims to enhance the prevention and control of birth defects, potentially improving maternal and fetal health outcomes.-Fineline Info & Tech
